menu
    • menu
    [{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ADX-324","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series C Financing","leadProduct":"ADX-324","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ADX-324","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"ADARx Pharmaceuticals \/ Ascenta Capital"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ SR One Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"ADARx Pharmaceuticals \/ SR One Capital Management"}]

    Find Clinical Drug Pipeline Developments & Deals by ADARx Pharmaceuticals

    Menu

    ADARx Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $200.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            ADARx Pharmaceuticals, a Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 Million Ser...

                            Details : The net proceeds will advance ADARx clinical programs including ADX-324, a siRNA designed to reduce the production of PKK, a protein critical to the etiology of hereditary angioedema, and ADX-038, under development for the treatment of paroxysmal nocturn...

                            Product Name : ADX-324

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            August 09, 2023

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $200.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324

                            Details : ADX-324 is a short-interfering RNA (siRNA) designed to reduce the production of PKK, a protein critical to the etiology of HAE. HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks.

                            Product Name : ADX-324

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            January 20, 2023

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Ascenta Capital

                            Deal Size : $46.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ADARx Pharmaceuticals Raises $46 Million as Lead Product Enters the Clinic

                            Details : The net proceeds will be used to advance ADARx’s proprietary RNA targeting platform together with novel oligonucleotide delivery technologies and to initiate phase I clinical trial of ADX-324 (siRNA duplex oligonucleotide), for the treatment of heredit...

                            Product Name : ADX-324

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 20, 2023

                            Lead Product(s) : ADX-324

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Ascenta Capital

                            Deal Size : $46.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            ADARx Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : SR One Capital Management

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ADARx Raises $75 Million to Advance Growing Pipeline

                            Details : The proceeds from the Series B financing will be used to advance ADARx’s proprietary RNA platform technologies for base editing, inhibition, degradation, and delivery.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            September 08, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : SR One Capital Management

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth